Lilly backs OrsoBio's $60M Series A for PhII trials in obesity and NASH
07 Nov 2023
OrsoBio, a biotech focused on obesity and metabolic disorders, is getting financial support from one of the leading drugmakers in the field as Eli Lilly helps back its $60 million Series A round.
OrsoBio, based in Menlo Park, CA, is an amalgamation of assets from Gilead, Shionogi, Phenex Pharmaceuticals and Astellas, and it already has candidates in human testing or clinical plans for obesity, type 2 diabetes, nonalcoholic steatohepatitis, as well as other inflammatory liver and kidney disorders.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.